CAM
IBRX icon

CenterStar Asset Management’s ImmunityBio IBRX Stock Holding History

CenterStar Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,600
Closed -$163K – 373
2026
Q1 		$165K Buy
+21,600
New +$148K 0.02% 451
2025
Q3 		– Sell
-20,000
Closed -$51.5K – 324
2025
Q2 		$52.7K Buy
20,000
+5,600
+39% +$15.1K 0.01% 193
2025
Q1 		$43.4K Buy
+14,400
New +$43.6K 0.01% 324

Other funds holding IBRX

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
MWM
MFG Wealth Management Indianapolis, Indiana $138M AUM 31.54% 1-Year Est. Return
CFO
Collective Family Office York, Pennsylvania $484M AUM 13.93% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $532M AUM 15.78% 1-Year Est. Return
CCIA
Cherry Creek Investment Advisors Englewood, Colorado $261M AUM 29.65% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $546M AUM 14.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PCA
Private Capital Advisors Darien, Connecticut $1.15B AUM 43.46% 1-Year Est. Return

CenterStar Asset Management's IBRX Position: Q2 2026 in Review

CenterStar Asset Management sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 21,600 shares — an estimated $163K sold.

CenterStar Asset Management first reported a position in IBRX in Q1 2025 and held it in 3 quarters. The position peaked at $165K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • CenterStar Asset Management reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • CenterStar Asset Management sold 21,600 ImmunityBio shares in Q2 2026, an estimated $163K.
  • CenterStar Asset Management first reported a position in ImmunityBio in Q1 2025 and held it in 3 quarters.
  • CenterStar Asset Management's ImmunityBio position peaked at $165K in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CenterStar Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.